129 related articles for article (PubMed ID: 36091934)
1. Improving outcomes for high-risk DLBCL: a pilot study looking at the role of fractionated cyclophosphamide with RCHOP chemo-immunotherapy (SCUBA-1 trial).
Singh C; Malhotra P; Jandial A; Jain A; Lad D; Khadwal A; Bal A; Das A; Mittal BR; Prakash G
Indian J Hematol Blood Transfus; 2023 Jan; 39(1):77-84. PubMed ID: 36091934
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis.
Yoon SE; Kim SJ; Yoon DH; Koh Y; Mun YC; Do YR; Choi YS; Yang DH; Kim MK; Lee GW; Suh C; Ko YH; Kim WS
Ann Hematol; 2020 Jun; 99(6):1283-1291. PubMed ID: 32333154
[TBL] [Abstract][Full Text] [Related]
3. Impact of Cell-of-Origin on Outcome of Patients With Diffuse Large B-Cell Lymphoma Treated With Uniform R-CHOP Protocol: A Single-Center Retrospective Analysis From North India.
Gogia A; Nair S; Arora S; Kumar L; Sharma A; Gupta R; Biswas A; Mallick S
Front Oncol; 2021; 11():770747. PubMed ID: 34926277
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B-cell non-Hodgkin lymphoma: ECOG3402.
Witzig TE; Hong F; Micallef IN; Gascoyne RD; Dogan A; Wagner H; Kahl BS; Advani RH; Horning SJ
Br J Haematol; 2015 Sep; 170(5):679-86. PubMed ID: 25974212
[TBL] [Abstract][Full Text] [Related]
5. Replacement of conventional doxorubicin by pegylated liposomal doxorubicin in standard RCHOP chemotherapy for elderly diffuse large B-Cell lymphoma: a retrospective study in China.
Zhou D; Li L; Bao C; Zhu J; Zhu L; Yang X; Zheng Y; Zhou M; Luo X; Xie W; Ye X
Int J Clin Exp Med; 2015; 8(12):22497-502. PubMed ID: 26885233
[TBL] [Abstract][Full Text] [Related]
6. Screening of key genes associated with R‑CHOP immunochemotherapy and construction of a prognostic risk model in diffuse large B‑cell lymphoma.
Liu R; Chen Z; Wang S; Zhao G; Gu Y; Han Q; Chen B
Mol Med Rep; 2019 Oct; 20(4):3679-3690. PubMed ID: 31485671
[TBL] [Abstract][Full Text] [Related]
7. Clinical Outcome of Rituximab-Based Therapy (RCHOP) in Diffuse Large B-Cell Lymphoma Patients with Bone Marrow Involvement.
Kang BW; Moon JH; Chae YS; Lee SJ; Kim JG; Kim YK; Lee JJ; Yang DH; Kim HJ; Kim JY; Do YR; Park KU; Song HS; Kwon KY; Kim MK; Lee KH; Hyun MS; Ryoo HM; Bae SH; Kim H; Sohn SK
Cancer Res Treat; 2013 Jun; 45(2):112-7. PubMed ID: 23864844
[TBL] [Abstract][Full Text] [Related]
8. How to determine post-RCHOP therapy for risk-tailored adult patients with diffuse large B-cell lymphoma, addition of maintenance rituximab or observation: multicenter experience.
Huang BT; Zeng QC; Yu J; Xiao Z; Li BS; Zhang CL; Ji HB
J Cancer Res Clin Oncol; 2012 Jan; 138(1):125-32. PubMed ID: 22057732
[TBL] [Abstract][Full Text] [Related]
9. The Role of Consolidative Radiotherapy after a Complete Response to Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma in the Rituximab Era: Results from a Systematic Review with a Meta-Analysis.
Hu C; Deng C; Zou W; Zhang G; Wang J
Acta Haematol; 2015; 134(2):111-8. PubMed ID: 25925586
[TBL] [Abstract][Full Text] [Related]
10. Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy.
Ennishi D; Yokoyama M; Terui Y; Asai H; Sakajiri S; Mishima Y; Takahashi S; Komatsu H; Ikeda K; Takeuchi K; Tanimoto M; Hatake K
Ann Oncol; 2009 Mar; 20(3):526-33. PubMed ID: 19074749
[TBL] [Abstract][Full Text] [Related]
11. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database.
LaCasce AS; Vandergrift JL; Rodriguez MA; Abel GA; Crosby AL; Czuczman MS; Nademanee AP; Blayney DW; Gordon LI; Millenson M; Vanderplas A; Lepisto EM; Zelenetz AD; Niland J; Friedberg JW
Blood; 2012 Mar; 119(9):2093-9. PubMed ID: 22234679
[TBL] [Abstract][Full Text] [Related]
12. Limited stage diffuse large B-cell lymphoma: comparative effectiveness of treatment strategies in a large cohort of elderly patients.
Odejide OO; Cronin AM; Davidoff AJ; LaCasce AS; Abel GA
Leuk Lymphoma; 2015 Mar; 56(3):716-24. PubMed ID: 24913508
[TBL] [Abstract][Full Text] [Related]
13. PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts.
Desai SH; Pederson L; LaPlant B; Mwangi R; Maurer M; Young JR; Macon WR; King RL; Wang Y; Cerhan JR; Feldman A; Inwards DJ; Micallef I; Johnston P; Porrata LF; Ansell SM; Habermann TM; Witzig TE; Nowakowski GS
Blood Cancer J; 2022 May; 12(5):78. PubMed ID: 35504884
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Value of Histone Modifying Enzyme EZH2 in RCHOP-Treated Diffuse Large B-Cell Lymphoma and High Grade B-Cell Lymphoma.
Petronilho S; Sequeira JP; Paulino S; Lopes P; Lisboa S; Chacim S; Lobo J; Teixeira M; Jerónimo C; Henrique R
J Pers Med; 2021 Dec; 11(12):. PubMed ID: 34945856
[TBL] [Abstract][Full Text] [Related]
15. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study.
Ji D; Cao J; Hong X; Li J; Wang J; Chen F; Wang C; Zou S
Eur J Haematol; 2010 Sep; 85(3):243-50. PubMed ID: 20491883
[TBL] [Abstract][Full Text] [Related]
16. Population-based outcome analysis of diffuse large B-cell lymphoma in people living with HIV infection and competent individuals.
Conconi A; Zucca E; Margiotta-Casaluci G; Darling K; Hasse B; Battegay M; Staehelin C; Novak U; Schmid P; Scherrer A; Dirnhofer S; Kwee I; Nassi L; Cavalli F; Gaidano G; Bertoni F; Bernasconi E;
Hematol Oncol; 2018 Dec; 36(5):757-764. PubMed ID: 30113708
[TBL] [Abstract][Full Text] [Related]
17. RCHOP-14 therapy versus RCHOP-21 therapy for people with aggressive or advanced-stage indolent B-cell non-Hodgkins lymphoma: a systematic review and meta-analysis.
He Y; Tao W; Ji D; Lu W; Xiong Y; Chen G
Transl Cancer Res; 2021 May; 10(5):2044-2054. PubMed ID: 35116526
[TBL] [Abstract][Full Text] [Related]
18. [Clinical outcome of 489 patients with diffuse large B-cell lymphoma and associated factors].
Wen JJ; Zhou JL; Liu ZB; Xu CG
Sichuan Da Xue Xue Bao Yi Xue Ban; 2014 May; 45(3):519-23. PubMed ID: 24941831
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Three Chemotherapy Regimens in Elderly Patients with Diffuse Large B Cell Lymphoma: Experience at a Single National Reference Center in Mexico.
Nolasco-Medina D; Reynoso-Noveron N; Mohar-Betancourt A; Aviles-Salas A; García-Perez O; Candelaria M
Biomed Res Int; 2016; 2016():9817606. PubMed ID: 27478844
[TBL] [Abstract][Full Text] [Related]
20. Clinical analysis and prognostic significance of hepatitis B virus infections for diffuse large B-cell lymphoma with or without rituximab therapy.
Xie W; Zhou D; Hu K; Xiao X; Huang W; He J; Shi J; Luo Y; Zhang J; Lin M; Cai Z; Huang H; Ye X
Exp Ther Med; 2013 Jul; 6(1):109-114. PubMed ID: 23935730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]